Ember LifeSciences has entered a capital and business alliance with Alfresa Corporation, the largest domestic pharmaceutical wholesaler in Japan by net sales, to improve the quality of pharmaceutical cold chain logistics across the country.1 The deal gives Alfresa exclusive sales rights to Ember's cold chain technology in Japan's healthcare sector and adds Alfresa as a Series A preferred stock investor in Ember, joining existing backers Amgen, Cardinal Health, Carrier and Sea Court Capital. Why Does the Deal Matter for Pharma Cold Chain Logistics? The Alfresa alliance builds on a run of commercial momentum for Ember. Ember LifeSciences, Inc. “Ember LifeSciences and Alfresa Corporation Enter into Capital and Business Alliance to Improve the Quality of the Pharmaceutical Cold Chain in Japan.” Ember LifeSciences, Inc. “Ember LifeSciences Introduces Ember Cube 2, Earns 'Best of the Best' Red Dot Design Award.”